RADNOR, PA — Delaware County, Pennsylvania-based Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) has announced that it will disclose its financial performance for the fourth quarter and the full year of 2023 on March 5, 2024. The pharmaceutical company plans to host a conference call later that day to provide an update on its operations and discuss the financial results in detail.
The conference call, scheduled for 4:30 p.m. E.T., is expected to provide valuable insights into the company’s financial health and future plans. Interested industry watchers can join the call domestically via (888) 550-5280 or internationally through (646) 960-0813. Participants will need to use the Conference ID: 2696394 to access the call.
In addition, Marinus Pharmaceuticals is offering a webcast registration for those who prefer to listen online. The webcast can be accessed through the events page on the company’s website.
Marinus Pharmaceuticals, known for its work in developing innovative treatments for rare seizure disorders, has drawn considerable attention from investors and industry analysts. The upcoming announcement of its financial results will likely shed light on how the company has navigated the challenges and opportunities of 2023.
An archived version of the call will be made available approximately two hours after the event concludes. This recording can be accessed by visiting the ‘Events and Presentations’ section of the Marinus website, providing an opportunity for those unable to attend the live call to catch up at their convenience.
As the date approaches, all eyes will be on Marinus Pharmaceuticals as industry watchers anticipate the company’s financial disclosures and updates on its strategic direction.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.